<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 20, 2019 (HealthDay News) — A consensus statement for the use of hematopoietic stem cell transplantation (HSCT) in the treatment of multiple myeloma (MM) has been developed by Mayo Clinic physicians; the recommendations were published in the March issue of Bone Marrow Transplantation<\/i>.<\/p>\n
Wilson I. Gonsalves, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues developed a consensus statement and provided evidence-based recommendations on the use of HSCT in MM.<\/p>\n
The authors note that autologous stem cell transplant (ASCT) remains an essential component of MM therapy in eligible patients in the era of novel agent induction therapy regimens. A delayed ASCT is safe and feasible upon first relapse, but an upfront ASCT remains the standard of care in eligible MM patients, especially those with high-risk disease. Performance status and comorbidities should be considered for ASCT eligibility in contrast to strict chronologic age cutoffs; depth of response to induction therapy should not dictate ASCT eligibility. Stem cells should be collected within six months of initiating therapy for all ASCT-eligible MM patients. A tandem ASCT within six months of the first ASCT should be considered in select patients with high-risk disease and good performance status. Routine use of a myeloablative or reduced-intensity conditioning allogeneic stem cell transplant is not recommended as upfront therapy except in the setting of a clinical trial or special circumstances.<\/p>\n
“ASCT remains an integral part of the management plan of all newly diagnosed MM patients who are otherwise eligible,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n